ABCSG-Publications (peer reviewed) 2006-2010
The publication of study results is an essential mandate of the ABCSG. Therapy improvements can only be made accessible to the entire medical-scientific community through publications. As a result, our knowledge of cancer is continuously increasing and the chances of winning the battle against it increase.
The publications listed here are the result of many years of successful work by the ABCSG.
Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?
Gnant M
Journal of Clinical Oncology
https://ascopubs.org/doi/full/10.1200/JCO.2010.29.6327
Neoadjuvant treatment and breast conserving surgery – a success of clinical research in breast cancer
Gnant M
Wiener Medizinische Wochenschrift
https://www.ncbi.nlm.nih.gov/pubmed/20473726
Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study
Lux M, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M, Thiel F
Onkologie
https://www.ncbi.nlm.nih.gov/pubmed/20631482
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and ist preditive value
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R
British Journal of Cancer
https://www.ncbi.nlm.nih.gov/pubmed/20877360
Potential Anticancer Properties of Bisphosphonates
Neville-Webbe HL, Gnant M, Coleman RE
Seminars in Oncology
https://www.sciencedirect.com/science/article/pii/S0093775410000874
Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There and Adjuvant Benefit?
Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth Ch, Samonigg H, Hüttner K, Fohler H, Rücklinger E, Jakesz, Greil R
Clinical Breast Cancer Supplement
https://www.ncbi.nlm.nih.gov/pubmed/19561003
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch Ch, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R
The New England Journal of Medicine
https://www.ncbi.nlm.nih.gov/pubmed/19213681
Her2/neu – neue Wege, neue Ziele
Mlinertisch B
Wiener Medizinische Wochenschrift
Anemia is a significant prognostic factor in local relaspe-free survival of premenopausal primary breast cancer patients receiving adjucant Cyclophosphamide/Methotrexate/5-Fluorouracil chemotherapy
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifer M, Denison U, Mlinertisch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M
Clinical Cancer Research
https://clincancerres.aacrjournals.org/content/14/7/2082
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Soelkner JC, Seifert M, Ploner F, Menzel Ch, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth Ch, Kubista E, Samonigg H, Wohlmuth P, Mittlboeck M, Jakesz R
The Lancet Oncology
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70204-3/fulltext
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
Mlinertisch B, Tausch Ch, Singer Ch, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel Ch, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R
Breast Cancer Research and Treatment
https://www.ncbi.nlm.nih.gov/pubmed/18158620
Cyclin D1 Expression in Breast Cancer Patients Receivin Adjucant Tamoxifen-Based Therapy
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer Ch, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant M, Filipits M
Clinical Cancer Research
https://www.ncbi.nlm.nih.gov/pubmed/18347178
The potential risk of neoadjuvant chemotherapy in breast cancer patients – results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)
Taucher S, Steger G, Jakesz R, Tausch Ch, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M
Breast Cancer Research and Treatment
Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel Ch, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/17159195
Extended Adjuvant Therapy with Anastrozole Among Postmenopausal Breast Cancer Patients: Results from the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch Ch, Stierer M, Hofbauer F, Renner K, Dadak Ch, Rücklinger E, Samonigg H
Journal of the National Cancer Institute
https://www.ncbi.nlm.nih.gov/pubmed/18073378
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer
Pötter R, Gnant M, Kwasny W, Tausch Ch, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G, Schmid M, Sedlmayr F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Pöstlberger S, Haider K, Draxler W, Jakesz R
International Journal for Radiation Oncology
https://www.ncbi.nlm.nih.gov/pubmed/17363187
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger G, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J
British Journal of Cancer
https://www.ncbi.nlm.nih.gov/pubmed/17895886
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
Steger G, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch Ch, Rudas M, Greil R, Wenzel C, Singer Ch, Haid An, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel Ch, Jakesz R
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/17513805
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
Mlineritsch B, Tausch Ch, Singer Ch, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel Ch, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R
Breast Cancer Res Treat DOI 10.1007/s10549-007-9843-x
https://www.ncbi.nlm.nih.gov/pubmed/18158620
The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)
Taucher S, Steger G, Jakesz R, Tausch Ch, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M
Breast Cancer Res Treat DOI 10.1007/s10549-007-9844-9
https://www.ncbi.nlm.nih.gov/pubmed/18080748
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF
Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski Ch, Lang A, Haid A, Jakesz R, Gnant M, Steger G
Breast Cancer Res Treat DOI 10.1007/s10549-006-9397-3
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis
Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R
The Lancet Oncology
Share on